NCT06850623 Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
| NCT ID | NCT06850623 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | EXACT Therapeutics AS |
| Condition | Locally Advanced Pancreatic Adenocarcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2025-06-19 |
| Primary Completion | 2026-12-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 25 participants in total. It began in 2025-06-19 with a primary completion date of 2026-12-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.
Eligibility Criteria
Inclusion Criteria: * Not deemed suitable for primary curative surgery and have radiographic and pathological disease consistent with inoperable LAPC or borderline resectable pancreatic cancer. * Suitable to receive treatment with mFOLFIRINOX according to the Investigator's assessment. Exclusion Criteria: • Any prior anti-cancer treatment for pancreatic cancer (e.g. chemotherapy, surgery, radiation). Palliative bypass procedure and bile duct stenting are allowed.
Frequently Asked Questions
Who can join the NCT06850623 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Locally Advanced Pancreatic Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06850623 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06850623 currently recruiting?
Yes, NCT06850623 is actively recruiting participants. Visit ClinicalTrials.gov or contact EXACT Therapeutics AS to inquire about joining.
Where is the NCT06850623 trial being conducted?
This trial is being conducted at Scottsdale, United States, Stanford, United States, Boston, United States, Detroit, United States and 6 additional locations.
Who is sponsoring the NCT06850623 clinical trial?
NCT06850623 is sponsored by EXACT Therapeutics AS. The trial plans to enroll 25 participants.